What is Skye Bioscience, Inc.'s current stock price?

Skye Bioscience, Inc. (SKYE) currently trades at USD 1.77. Track real-time price changes and historical performance on AllInvestView.

What sector is Skye Bioscience, Inc. in?

Skye Bioscience, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Skye Bioscience, Inc. SKYE · Stock Open Skye Bioscience, Inc. in new tab

1.77 USD

Add to portfolio

EPS

-10.24

P/B

-17.48

ROE

-233.87

Beta

2.90

Target Price

68.00 USD

Skye Bioscience, Inc.

🧾 Earnings Recap – Q3 2025

Skye Bioscience, Inc. delivered promising data from its Phase 2a CBEYOND study, demonstrating strong efficacy of Nimazumab in combination with semaglutide and reporting a net loss of $12.8 million for Q3 2025.

Cash reserves stood at $35.3 million, expected to fund operations through 2027.
R&D expenses rose to $9.4 million, reflecting increased clinical trial activity and manufacturing costs.
Positive findings from the CBEYOND study revealed a 30% improvement in weight loss efficacy when combining Nimazumab with semaglutide.
Data also demonstrated enhanced metabolic benefits and safety with no significant adverse effects observed.
Enrollment in a 26-week extension study was completed, with results anticipated by late Q1 2026.

All SKYE earnings recaps View full recap page

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Skye Bioscience, Inc. (SKYE)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Skye Bioscience, Inc. Analysis (SKYE)

United States Health Care Official Website Stock

Is Skye Bioscience, Inc. a good investment? Skye Bioscience, Inc. (SKYE) is currently trading at 1.77 USD. Market analysts have a consensus price target of 68.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Skye Bioscience, Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -7.40.

Investor FAQ

Does Skye Bioscience, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Skye Bioscience, Inc.?

Skye Bioscience, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -10.24.

Company Profile

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.

Exchange Ticker

PNK (United States) SKYE

Trades

Dividend History paid per year (USD)

No dividend history available.

Stock Splits

Split Date	Split Ratio to 1
Sept. 8, 2023	Needs review
Aug. 24, 2026	1:8

Fundamentals

Twitter YouTube Reddit Feature Requests Changelog Support Pricing Help

Support email: [email protected]

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.

Skye Bioscience, Inc. SKYE · Stock Open Skye Bioscience, Inc. in new tab

Skye Bioscience, Inc.

Key Metrics

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Skye Bioscience, Inc. Analysis (SKYE)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Skye Bioscience, Inc. SKYE · Stock Open Skye Bioscience, Inc. in new tab

Key Metrics

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Skye Bioscience, Inc. Analysis (SKYE)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications